<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271412</url>
  </required_header>
  <id_info>
    <org_study_id>LY03005 MAD</org_study_id>
    <secondary_id>LY03005/CT-USA-102</secondary_id>
    <nct_id>NCT02271412</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives

        -  To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in
           healthy subjects.

        -  To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled, multiple ascending dose study to
      be conducted in the US. Approximately 48 healthy subjects will be enrolled into one of the
      four groups
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>3 to 4 months</time_frame>
    <description>Safety and Tolerability of LY03005</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Major Depressive Disorder, Recurrent, Unspecified</condition>
  <arm_group>
    <arm_group_label>LY03005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY03005 40, 80, 120, or 160 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo at 40, 80, 120, or 160 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY03005</intervention_name>
    <description>LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.</description>
    <arm_group_label>LY03005</arm_group_label>
    <other_name>4-Methylbenzoate of desvenlafaxine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are capable of giving informed consent and complying with study procedures;

          2. Are between the ages of 18 and 45 years, inclusive;

          3. A negative pregnancy test result prior to screening and admission for all female
             subjects, and meet the following criteria defined as:

               1. If child-bearing potential, agree to avoid pregnancy during the study and one
                  month after the end of the study by using effective contraceptive method(s), such
                  as an intrauterine device (IUD), diaphragm with spermicide, and condoms with
                  spermicide.

               2. Surgically sterile for at least 3 months prior to screening

               3. Postmenopausal

          4. Considered healthy by the Principal Investigator, based on a detailed medical history,
             full physical examination, clinical laboratory tests, 12-lead ECG and vital signs;

          5. Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6
             months before screening;

          6. Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 50 kg;

          7. Willing and able to adhere to study restrictions and to be confined at the clinical
             research center.

        Exclusion Criteria:

        Subjects will be excluded from study entry if any of the following exclusion criteria are
        present at screening or admission:

          1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,
             immunologic, lipid metabolism disorders, or drug hypersensitivity;

          2. Subjects with a mean systolic blood pressure of three measurements less than 130 mmHG,
             or a mean diastolic blood pressure of three measurements less than 90 mmHG at
             screening. Blood pressure will be measured at supine position.

          3. Known or suspected malignancy;

          4. Positive blood screen for human immunodeficiency virus (HIV), or hepatitis B surface
             antigen (HBsAg), or hepatitis C virus;

          5. A history of seizure. However, a history of febrile seizure is allowed;

          6. Positive pregnancy test result, or plan to become pregnant if female;

          7. A hospital admission or major surgery within 30 days prior to screening;

          8. Participation in any other investigational drug trial within 30 days prior to
             screening;

          9. DSM-V substance use disorder within 6 months prior to screening;

         10. A positive result for alcohol or drugs of abuse at screening or admission;

         11. Tobacco use within 6 months prior to screening;

         12. An unwillingness or inability to comply with food and beverage restrictions during
             study participation;

         13. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or
             blood products) or acute loss of blood during the 90 days prior to screening;

         14. Use of prescription or over-the-counter (OTC) medications, and herbal medicines
             (including St John's Wort, herbal teas, garlic extracts)within 14 days prior to dosing
             (Note: Use of acetaminophen at &lt; 3g/day is permitted until 24 hours prior to dosing);

         15. A history of intolerance or hypersensitivity to venlafaxine or desvenlafaxine or any
             excipients;

         16. A history of suicide attempt in the past 12 months and/or seen by the investigator as
             having a significant history of risk of suicide or homicide; 17 An unwillingness of
             male participants to use appropriate contraceptive measures if engaging in sex
             intercourse with a female partner of childbearing potential. Appropriate measures
             include use of a condom and spermicide and, for female partners, use of an
             intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable
             progesterone, progesterone sub-dermal implants, or a tubal ligation. Sexual
             intercourse with pregnant or lactating women is prohibited.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Krefetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA - CRI Lifetree</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

